Pfizer is paying BioNTech $225 million to kick off a new alliance aiming to develop a shingles vaccine based on the same messenger RNA technology that is the basis of the partners' Covid-19 vaccine. It’s the third alliance between the two companies, but this time Pfizer brings something more to the table.
Specialty pain meds maker Scilex Pharmaceuticals plans to wrap up clinical trials for its lead product, Ztildo – and has just raised $5 million from private investors to do so, according to regulatory filings. Ztildo is a lidocaine patch developed specifically for a form of neuralgia that often follows shingles infections. It has licensed the technology from a […]
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.